Cargando…

Upregulation of microRNA-16 alters the response to inhaled β-agonists in patients with asthma though modulating expression of ADRB2

MicroRNAs (miRNAs) are non-coding RNAs of ~22 nucleotides in length, which serve an important role in numerous diseases. Asthma is a chronic airway inflammatory disease, which is the most common chronic disease among children. The role of miRNA (miR)-16 in asthma is unclear. The objective of the pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Bo, Yao, Lusu, Liu, Cuiqiao, Tang, Lina, Xing, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6471313/
https://www.ncbi.nlm.nih.gov/pubmed/30942450
http://dx.doi.org/10.3892/mmr.2019.10097
_version_ 1783412000172277760
author Yu, Bo
Yao, Lusu
Liu, Cuiqiao
Tang, Lina
Xing, Tao
author_facet Yu, Bo
Yao, Lusu
Liu, Cuiqiao
Tang, Lina
Xing, Tao
author_sort Yu, Bo
collection PubMed
description MicroRNAs (miRNAs) are non-coding RNAs of ~22 nucleotides in length, which serve an important role in numerous diseases. Asthma is a chronic airway inflammatory disease, which is the most common chronic disease among children. The role of miRNA (miR)-16 in asthma is unclear. The objective of the present study was to examine the underlying molecular mechanism of the involvement of miR-16 in asthma. A total of 72 volunteers diagnosed with asthma consented to participate in the study, of whom 52 participants were identified to be sensitive to salmeterol and 20 participants were identified to be resistant to salmeterol. Receiver operating characteristic (ROC) curve analysis was performed to compare the expression levels of serum miR-16 between the sensitive and resistant groups, and to confirm the association between the expression level of serum miR-16 and forced expiratory volume in 1 sec (FEV1). In silico analysis, a luciferase assay, reverse transcription-quantitative polymerase chain reaction analysis and western blotting were performed to elucidate the molecular mechanism underlying the role of miR-16 in asthma. ROC results demonstrated that the serum miR-16 level may function as a biomarker to predict the response to salmeterol therapy, and the miR-16 expression level displayed a significant negative correlation with FEV1. According to the in silico analysis, adrenoreceptor β-2 (ADRB2) was a direct target of miR-16, and it was further confirmed by luciferase assay that 25 nM miR-16 mimic had an inhibitory effect on the luciferase activity of the wild-type ADRB2 3′ untranslated region (UTR); the inhibitory effect on the luciferase activity of the wild-type ADRB2 3′UTR was stronger with 50 nM miR-16 mimic, and strongest with 75 nM miR-16 mimic, whereas the luciferase activity of the mutant ADRB2 3′UTR in cells was similar following treatment with 0, 25, 50 or 75 nM miR-16 mimic. miR-16 reduced the mRNA and protein expression levels of ADRB2 in a dose-dependent manner. These results identified that miR-16 may be used as a predictive biomarker of therapeutic response in asthma.
format Online
Article
Text
id pubmed-6471313
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-64713132019-04-23 Upregulation of microRNA-16 alters the response to inhaled β-agonists in patients with asthma though modulating expression of ADRB2 Yu, Bo Yao, Lusu Liu, Cuiqiao Tang, Lina Xing, Tao Mol Med Rep Articles MicroRNAs (miRNAs) are non-coding RNAs of ~22 nucleotides in length, which serve an important role in numerous diseases. Asthma is a chronic airway inflammatory disease, which is the most common chronic disease among children. The role of miRNA (miR)-16 in asthma is unclear. The objective of the present study was to examine the underlying molecular mechanism of the involvement of miR-16 in asthma. A total of 72 volunteers diagnosed with asthma consented to participate in the study, of whom 52 participants were identified to be sensitive to salmeterol and 20 participants were identified to be resistant to salmeterol. Receiver operating characteristic (ROC) curve analysis was performed to compare the expression levels of serum miR-16 between the sensitive and resistant groups, and to confirm the association between the expression level of serum miR-16 and forced expiratory volume in 1 sec (FEV1). In silico analysis, a luciferase assay, reverse transcription-quantitative polymerase chain reaction analysis and western blotting were performed to elucidate the molecular mechanism underlying the role of miR-16 in asthma. ROC results demonstrated that the serum miR-16 level may function as a biomarker to predict the response to salmeterol therapy, and the miR-16 expression level displayed a significant negative correlation with FEV1. According to the in silico analysis, adrenoreceptor β-2 (ADRB2) was a direct target of miR-16, and it was further confirmed by luciferase assay that 25 nM miR-16 mimic had an inhibitory effect on the luciferase activity of the wild-type ADRB2 3′ untranslated region (UTR); the inhibitory effect on the luciferase activity of the wild-type ADRB2 3′UTR was stronger with 50 nM miR-16 mimic, and strongest with 75 nM miR-16 mimic, whereas the luciferase activity of the mutant ADRB2 3′UTR in cells was similar following treatment with 0, 25, 50 or 75 nM miR-16 mimic. miR-16 reduced the mRNA and protein expression levels of ADRB2 in a dose-dependent manner. These results identified that miR-16 may be used as a predictive biomarker of therapeutic response in asthma. D.A. Spandidos 2019-05 2019-03-28 /pmc/articles/PMC6471313/ /pubmed/30942450 http://dx.doi.org/10.3892/mmr.2019.10097 Text en Copyright: © Yu et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Yu, Bo
Yao, Lusu
Liu, Cuiqiao
Tang, Lina
Xing, Tao
Upregulation of microRNA-16 alters the response to inhaled β-agonists in patients with asthma though modulating expression of ADRB2
title Upregulation of microRNA-16 alters the response to inhaled β-agonists in patients with asthma though modulating expression of ADRB2
title_full Upregulation of microRNA-16 alters the response to inhaled β-agonists in patients with asthma though modulating expression of ADRB2
title_fullStr Upregulation of microRNA-16 alters the response to inhaled β-agonists in patients with asthma though modulating expression of ADRB2
title_full_unstemmed Upregulation of microRNA-16 alters the response to inhaled β-agonists in patients with asthma though modulating expression of ADRB2
title_short Upregulation of microRNA-16 alters the response to inhaled β-agonists in patients with asthma though modulating expression of ADRB2
title_sort upregulation of microrna-16 alters the response to inhaled β-agonists in patients with asthma though modulating expression of adrb2
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6471313/
https://www.ncbi.nlm.nih.gov/pubmed/30942450
http://dx.doi.org/10.3892/mmr.2019.10097
work_keys_str_mv AT yubo upregulationofmicrorna16alterstheresponsetoinhaledbagonistsinpatientswithasthmathoughmodulatingexpressionofadrb2
AT yaolusu upregulationofmicrorna16alterstheresponsetoinhaledbagonistsinpatientswithasthmathoughmodulatingexpressionofadrb2
AT liucuiqiao upregulationofmicrorna16alterstheresponsetoinhaledbagonistsinpatientswithasthmathoughmodulatingexpressionofadrb2
AT tanglina upregulationofmicrorna16alterstheresponsetoinhaledbagonistsinpatientswithasthmathoughmodulatingexpressionofadrb2
AT xingtao upregulationofmicrorna16alterstheresponsetoinhaledbagonistsinpatientswithasthmathoughmodulatingexpressionofadrb2